Title |
Selective serotonin reuptake inhibitors for premenstrual syndrome
|
---|---|
Published in |
Cochrane database of systematic reviews, June 2013
|
DOI | 10.1002/14651858.cd001396.pub3 |
Pubmed ID | |
Authors |
Jane Marjoribanks, Julie Brown, Patrick Michael Shaughn O'Brien, Katrina Wyatt |
Abstract |
Premenstrual syndrome (PMS) is a common cause of physical, psychological and social problems in women of reproductive age. The key characteristic of PMS is the timing of symptoms, which occur only during the two weeks leading up to menstruation (the luteal phase of the menstrual cycle). Selective serotonin reuptake inhibitors (SSRIs) are increasingly used as first line therapy for PMS. SSRIs can be taken either in the luteal phase or else continuously (every day). SSRIs are generally considered to be effective for reducing premenstrual symptoms but they can cause adverse effects. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 25% |
United Kingdom | 3 | 19% |
France | 1 | 6% |
Austria | 1 | 6% |
Mexico | 1 | 6% |
Unknown | 6 | 38% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 56% |
Practitioners (doctors, other healthcare professionals) | 5 | 31% |
Scientists | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 497 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | <1% |
Netherlands | 1 | <1% |
United Kingdom | 1 | <1% |
Peru | 1 | <1% |
Greece | 1 | <1% |
Unknown | 492 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 77 | 15% |
Student > Master | 58 | 12% |
Researcher | 44 | 9% |
Student > Doctoral Student | 43 | 9% |
Student > Ph. D. Student | 35 | 7% |
Other | 93 | 19% |
Unknown | 147 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 161 | 32% |
Psychology | 48 | 10% |
Nursing and Health Professions | 38 | 8% |
Neuroscience | 18 | 4% |
Agricultural and Biological Sciences | 13 | 3% |
Other | 54 | 11% |
Unknown | 165 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 211. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2023.
All research outputs
#186,054
of 25,576,801 outputs
Outputs from Cochrane database of systematic reviews
#318
of 13,155 outputs
Outputs of similar age
#1,177
of 210,233 outputs
Outputs of similar age from Cochrane database of systematic reviews
#11
of 302 outputs
Altmetric has tracked 25,576,801 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,155 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,233 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 302 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.